Tenax Therapeutics, Inc.
NASDAQ:TENXBiotechnology
+$0.10 today
- Market cap
- $50.66M
- Beta
- 0.97
- P/E (TTM)
- -9.4
- EPS (TTM)
- -$1.28
Volume 0.70M
Average 0.62M
TENX Account Payables
Amounts the company owes suppliers for goods and services received.
Tenax Therapeutics, Inc.NASDAQ: TENX
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 245.1% from a year ago
Account payables stood at $6.35M at the end of Q1 FY2026, up 245.1% from a year earlier and up 5.0% from the prior quarter. Over 3 fiscal years it compounded at +137.9% a year.
Context
- Account payables amounted to 5.2% of total assets at the end of Q1 FY2026, up 3.5 pp from a year earlier.
- Account payables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +245.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 6.04M USD
- Year-over-year change
- +91.4%
- 4-year CAGR
- +62.8%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.04M | +91.4% |
| FY2024 | 2024-12-31 | 3.16M | +52.3% |
| FY2023 | 2023-12-31 | 2.07M | +362.3% |
| FY2022 | 2022-12-31 | 448.43K | -47.8% |
| FY2021 | 2021-12-31 | 859.64K | — |
Account Payables vs competitors
How TENX compares with its peers on the latest reported figures
- TENX's Mar 2026 account payables of $6.35M is the highest of the 7 companies compared; the peer median is $2.11M.
- Its year-over-year change of +245.1% is the highest of 7, against a peer median of +48.0%.
- Account payables amounts to 5.2% of total assets for TENX, versus a peer median of 1.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $6.35M | +245.1% | +137.9% | 5.2% | |
| Jun 2026 | $3.86M | +47.0% | -5.1% | 1.6% | |
| Mar 2026 | $2.62M | -14.9% | +12.5% | 3.0% | |
| Mar 2026 | $2.19M | +52.0% | +59.9% | 5.7% | |
| Mar 2026 | $2.04M | +49.0% | +2.1% | 1.4% | |
| Jun 2026 | $1.45M | +61.5% | -13.0% | 0.0% | |
| Mar 2026 | $653K | -75.9% | -15.1% | 1.0% | |
| Peer median (excluding TENX) | $2.11M | +48.0% | -1.5% | 1.5% | |
Competitors are the stored peer set for TENX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Tenax Therapeutics, Inc.
NASDAQ:TENX
Intrinsic Alpha fair value
Locked
Current Price
$1.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.